NASDAQ:PRTC PureTech Health (PRTC) Stock Price, News & Analysis $17.42 0.00 (0.00%) As of 11/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About PureTech Health Stock (NASDAQ:PRTC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PureTech Health alerts:Sign Up Key Stats Today's Range$17.42▼$17.4250-Day Range$17.42▼$17.4252-Week Range$14.50▼$19.92VolumeN/AAverage Volume18,480 shsMarket Capitalization$424.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PureTech Health plc is a biotherapeutics company that discovers and develops medicines for serious diseases. Founded in 2015, the company advances treatments through a portfolio of wholly owned programs and separately operating companies it has helped establish.Its research has covered areas including immunology, oncology and neuroscience, using scientific and technology platforms to pursue new therapeutic approaches. PureTech’s work is focused on developing drug candidates rather than providing healthcare services or operating a broad marketed-product business.One company PureTech founded was Karuna Therapeutics, which developed xanomeline and trospium for schizophrenia. The treatment was approved in the United States as Cobenfy in 2024, after Bristol Myers Squibb acquired Karuna.AI Generated. May Contain Errors. Read More Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTC Stock News HeadlinesPRTC's Gallop to Present Ph1b LYT-200 Data at ESMOOctober 19, 2026 | markets.ft.comPRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNPOctober 11, 2026 | markets.ft.comUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.November 17 at 1:00 AM | Paradigm Press (Ad)PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of ...October 9, 2026 | finance.yahoo.comPureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...July 13, 2026 | finance.yahoo.comPureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)July 13, 2026 | uk.finance.yahoo.comPureTech entity Celea raises $180 million to move lung disease drug into late stage trialJuly 2, 2026 | reuters.comPureTech Health plc American Depositary Shares (PRTC) Real-TimeJuly 1, 2026 | nasdaq.comSee More Headlines PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed this year? PureTech Health's stock was trading at $17.1150 on January 1st, 2026. Since then, PRTC shares have increased by 1.8% and is now trading at $17.42. Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (38m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PRTC's financial health is in the Red zone, according to TradeSmith. PRTC has been in this zone for over 38 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRTC CIK1782999 Webwww.puretechhealth.com Phone617-482-2333Fax617-482-3337Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.59 Quick Ratio6.59 Sales & Book Value Annual Sales$4.66 million Price / Sales91.01 Cash FlowN/A Price / Cash FlowN/A Book Value$12.65 per share Price / Book1.38Miscellaneous Outstanding Shares24,342,000Free Float23,052,000Market Cap$424.04 million OptionableNot Optionable Beta1.15 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:PRTC) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.